We understand that managing obesity and achieving sustainable weight loss requires personalized care and clinical expertise
However, other GLP-1 analogues used either as monotherapy or in combination with other drug classes have the potential to encourage additional weight loss in people with obesity [26], but are currently not licensed for this use and are licensed for use in T2D alone
Keep reading Published on: September 17, 2025 JohnElliottCare John Elliott was a builder who enjoyed meeting with clients and planning their future homes
Companies will be angling to be the first to file the application needed to receive US Food and Drug Administration approval to market generic semaglutide
Scientists see possible links, but the evidence is still far from definitive This is a human-written story voiced by AI
Non-acylated GLP-1RAs, such as exenatide, significantly penetrate the BBB and affect brain regions like the hypothalamus, which controls appetite